Lannett’s Insulin Aspart Biosimilar Takes ‘Major Step’ Forward
Lannett’s Insulin Aspart On Track For Key Development Milestones After Positive Animal Study Results
Lannett's Insulin Aspart Is A Major Pipeline Asset For the US Firm • Source: Shutterstock 
